Financial Viability: EquiTrak Pro
Product: EquiTrak Pro
3-Year Financial Projection | Markets: India, UAE, Thailand
Net Present Value
$2.1M
10% discount rate
Internal Rate of Return
34%
Hurdle rate: 15%
Break-Even Period
14 months
From first sale
3-Year ROI
145%
Cumulative return
Revenue Projections
| Year | Units Sold | Avg Selling Price | Revenue | COGS | Gross Margin |
|---|---|---|---|---|---|
| Year 1 | 24 | $32,000 | $768K | $307K | 28% |
| Year 2 | 58 | $30,500 | $1.77M | $620K | 34% |
| Year 3 | 112 | $29,000 | $3.25M | $975K | 36% |
| 3-Year Total | 194 | — | $5.79M | $1.90M | 33% avg |
Investment Breakdown
Regulatory
$180K
Registrations × 3 markets
Inventory
$320K
Initial stock & demo units
Marketing
$150K
Launch campaigns & KOLs
Clinical
$90K
Studies & evidence gen
Total Investment Required
$740,000
AI ROI Insights
- IRR of 34% significantly exceeds the 15% hurdle rate — strong financial case for proceeding
- Break-even at 14 months is excellent for a medtech distribution play in emerging markets
- Gross margin expansion from 28% → 36% by Y3 driven by volume discounts and market maturation. Medtech hardware distribution in emerging markets typically achieves 28–38% gross margins
- Regulatory investment ($180K) is the critical path item — delays here push break-even by ~3 months
- Recommend phasing inventory build to reduce upfront capital exposure in Y1